Loading...
NASDAQ: ARCT
Arcturus Therapeutics Holdings Inc.
Healthcare · Biotechnology
Market Cap
$186.17M
52w High
$24.17
52w Low
$5.85
P/E
-2.73
Volume
539.76K
Outstanding Shares
28.42M
Company profile
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States.
CEOJoseph E. Payne
SectorHealthcare
IndustryBiotechnology
Employees174
IPO dateMay 22, 2013
Valuation
Forward P/E—
EV/EBITDA0.53
Enterprise value-$38.03M
Stock splits
Nov 16, 20171:7
Profitability & growth
Revenue growth-85.33%
Gross margin94.57%▼4.50%vs FY2024
Operating margin-101.12%▼61.30%vs FY2024
ROE-30.74%▲8.48%vs FY2024
Analyst consensus
RatingBuy
Target price$22.50▲243.51%
11
Buy
6
Hold
4
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 11, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
-$0.34
-$1.11
Q3FY25
ActualEst.
-$0.49
-$0.80
Q4FY25
ActualEst.
-$1.03
-$0.78
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
$24.51M
$18.34M
Q3FY25
ActualEst.
$17.15M
$16.03M
Q4FY25
ActualEst.
$3.08M
$11.35M
Q1FY26
Next Est.
—